RE: talks etc22 May 2018 10:50
lol, the people who ramble on about PR may be disappointed, but what in reality did they expect?
The company, who have made mistakes along the way, have regularly updated us with the news they are allowed to share. The rest is probably not permitted to be shared yet.
In terms of PR, they are a small AIM biotech, they are not Coca Cola, but they still manage at least 10-20 comms per year, RNS updates, videos, calls, investor evenings/presentations, UK investor show etc. Do you want a front page spread on the metro? Perhaps a �20m viral easter egg campaign? Perhaps we could hire Lord Mandelsson to lobby parliament?
In the grand scheme of things, I half wonder if the incessant rambling about improved PR is whining by PR marketeers who are simply trying to sell their services to Valirx. PR will not radically improve Valirx's position. A commercially efficacious drug with decent safety will do wonders.
As you can probably tell, I am not a fan of ad-men, and frankly the BRR media/proactive investor interviews are serially embarrassing for any AIM company, because it basically is paid-for PR flagging a probable imminent equity issue.